Drugs / MBL949
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05199090 Comparator | Feb 2022 → May 2023 | obesity disorder | Novartis Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBL949 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05199090 ↗ |
| Route | Subcutaneous | “subcutaneous injections administered for 14 weeks” NCT05199090 ↗ |